BiSTC Portfolio - Completed Trials

BiSTC trials portfolio - our completed trials are listed below. Please follow the hyperlinks to the specific trials websites which contain further information about each study, who to contact and any publications arising from the research.

Table of completed trials in the BiSTC portfolio
	BILCAP: A randomised clinical trial evaluating adjuvant chemotherapy with capecitabine compared to expectant treatment alone following surgery for biliary tract cancer Speciality: Upper GI Chief Investigator: Professor John Primrose Funded By: CRUK Portfolio Study ID: 1473 Phase: Phase III Initial Target Number of Patients: 410
	FIAT: The Fistula-In-Ano Trial comparing Surgisis® anal fistula plug versus surgeon’s preference for transsphincteric fistula-in-ano Speciality: Colorectal Chief Investigator: Professor David Jayne Funded By: HTA Portfolio Study ID: 9592 Phase: Phase III Initial Target Number of Patients: 500
	HYMN: A randomised, controlled, phase III trial comparing hyperthermia plus mitomycin (HM) to a second course of bacillus Calmette-Guérin (BCG) or standard therapy in patients with recurrence of non-muscle invasive bladder cancer following induction or maintenance BCG therapy Speciality: Bladder Cancer Chief Investigator: Professor John Kelly Funded By: CRUK Portfolio Study ID: 6553 Phase: Phase III Initial Target Number of Patients: 242
	PEGASUS: A feasibility study and open pilot two-arm randomised controlled trial comparing Pressure Garment Therapy with no Pressure Garment Therapy for the prevention of abnormal scarring after burn injury (PEGASUS) Speciality: Plastics Chief Investigator: Mr Naiem Moiemen Funded By: NIHR HTA Portfolio Study ID: 17346 Phase: Pilot/Feasibility Initial Target Number of Patients: 88
	ROCSS: Reinforcement of Closure of Stoma Site. A randomised controlled trial of reinforcement of closure of stoma site using a biological mesh Speciality: Colorectal Chief Investigator: Mr Aneel Bhangu Funded By: LifeCell/RfPB Portfolio Study ID: 13461 Phase: Phase III Initial Target Number of Patients: 90
	VITTAL: Viability Testing and Transplantation of Marginal Livers Speciality: Liver Transplantation Chief Investigator: Professor Darius Mirza Funded By: Wellcome Trust Portfolio Study ID: 32299 Phase: Phase I/II Initial Target Number of Patients: 23